Contact Us
Drug Search Results
More Filters [+]

Dorzolamide

Alternative Names: dorzolamide, trusopt, cosopt pf, cosopt
Latest Update: 2024-11-06
Latest Update Note: Clinical Trial Update

Product Description

Dorzolamide ophthalmic (eye) drops is used to treat increased pressure in the eye caused by open-angle glaucoma or a condition called hypertension of the eye. Both eye conditions are caused by high pressure in your eye and can lead to pain from pressure in your eye and then can eventually harm your vision. (Sourced from: https://www.mayoclinic.org/drugs-supplements/dorzolamide-ophthalmic-route/side-effects/drg-20063524?p=1)

Mechanisms of Action: CA Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Intraocular,Ophthalmic

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: Hypertension | Glaucoma | Glaucoma, Open-Angle | Hypertension | Glaucoma | Glaucoma, Open-Angle

Known Adverse Events: Keratitis | Ocular Discomfort

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dorzolamide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

09/26/2023

News Article

 Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

05/30/2023

News Article

 Thea Pharma Inc. Launches Preservative Freedom Coalition to Advocate for Preservative-free Eye Care

04/28/2023

News Article

 Thea Pharma Inc. Statement Related to Akorn's Voluntary Nationwide Recall of Various Human and Animal Drug Branded Ophthalmic Products within Expiry Due to Company Shutdown

04/12/2023

News Article

 Open-angle glaucoma therapeutics market size to grow by USD 2.58 billion from 2021 to 2026; AbbVie Inc. and Aerie Pharmaceuticals Inc, among others, emerge as key vendors - Technavio

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions